Partnering with Your Healthcare Provider
Managing fibromyalgia may often require a team approach involving several healthcare providers. Depending on your symptoms, you may need to see a:
- Primary care or family physician
- Rheumatologist
- Pain management specialist
- Physical therapist
- Psychiatrist or other counselor
It is important to work with your healthcare provider to develop a treatment plan that addresses your particular symptoms. Sharing your answers to the Fibromyalgia Doctor Discussion Guide is a great conversation starter.
Your doctor may ask you questions such as:
- What kind of symptoms are you experiencing?
- How do these symptoms impact your life?
- What do you think causes these symptoms?
- What do you think makes your symptoms worse?
In addition to your healthcare team, there are a number of organizations and support groups ready to help you learn more about fibromyalgia and how to manage it. Please discuss the resources available with your healthcare provider.
Important Safety Information
Cymbalta® (duloxetine HCl) is approved for the treatment of depression and generalized anxiety disorder, and for the management of diabetic peripheral neuropathic pain and fibromyalgia.
What should I talk about with my healthcare provider?
Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, unusual changes in behavior, thoughts of suicide, anxiety, agitation, panic attacks, difficulty sleeping, irritability, hostility, aggressiveness, impulsivity, restlessness, or extreme hyperactivity. Call your healthcare provider right away if you have thoughts of suicide or if any of these symptoms are severe or occur suddenly. Be especially observant within the first few months of antidepressant treatment or whenever there is a change in dose.
You should also know that:
- Suicide is a known risk of depression and some other psychiatric disorders.
- Antidepressants may increase suicidal thoughts or behaviors in some children, adolescents, and young adults especially within the first few months of treatment or when changing the dose. No increased risk has been shown for adults over age 24, and risk decreased for those over age 65.
- All patients starting therapy should be monitored appropriately and observed closely for new or worsening depression symptoms.
- Cymbalta is not approved for use in patients under age 18.
Who should NOT take Cymbalta?
You should not take Cymbalta if:
- You have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI)
- You have uncontrolled narrow-angle glaucoma (an eye disease)
- You are taking Mellaril® (thioridazine)
What other important information should I discuss with my healthcare provider?
Before starting Cymbalta, tell your healthcare provider:
- about all of your medical conditions, including kidney problems, glaucoma, or diabetes
- about your alcohol use
- if you are taking nonprescription or prescription medicines, including those for migraine, to address a possible life-threatening condition
- if you are taking NSAID pain relievers, aspirin, or blood thinners. Use with Cymbalta may increase bleeding risk
- if you are pregnant, plan to become pregnant during therapy, or are breastfeeding an infant
While taking Cymbalta, tell your healthcare provider:
- if you have itching, right upper belly pain, dark urine, yellow skin/eyes, or unexplained flu-like symptoms, which may be signs of liver problems. Severe liver problems, sometimes fatal, have been reported
- if you have high fever, confusion, and stiff muscles to address a possible life-threatening condition
- before stopping Cymbalta or changing your dose
- if you experience dizziness or fainting upon standing, especially when first starting Cymbalta or when increasing the dose. Your healthcare provider may periodically check your blood pressure while you are taking Cymbalta
If you have any questions, talk to your healthcare provider before taking Cymbalta.
What are the possible side effects of Cymbalta?
The most common side effect of Cymbalta was nausea. For most people who had it, the nausea was mild to moderate. Other common side effects included dry mouth, sleepiness, constipation, decreased appetite, and, increased sweating. This is not a complete list of side effects.
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN - USA
Mellaril is a registered trademark of its manufacturer.
DD56879 © 2009 Lilly USA, LLC. All rights reserved.
Cymbalta is a registered trademark of Eli Lilly and Company.
WebMD does not endorse any specific product, service, or treatment.
Safety Information and Boxed Warning
Prescribing Information | Medication Guide

